Virocell Adds J. David Enloe and Dr. Martin Pule to its Board of Directors

David and Martin join Virocell to scale the organization to meet the explosive demand from clients for viral vectors for clinical trials.

Fremont, CA: ViroCell is addressing the global viral vector supply-demand imbalance, which is limiting the production of novel cell and gene therapies. ViroCell is solely dedicated to the design and GMP production of viral vectors and gene-modified cells for clinical trials. ViroCell aspires to be the preferred global supplier of viral vectors during the translational phase of developing novel cell and gene therapies.

J. David Enloe, Jr.'s appointment to the Board of Directors brings nearly three decades of executive leadership in the CDMO and biotechnology industries, including first-mover experience in GMP viral vector manufacturing. David is the President and CEO of Recro Pharma, a CDMO specializing in novel formulation development and clinical to commercial-scale pharmaceutical product manufacturing. He was the President and CEO of Ajinomoto Bio-Pharma Services, a global, fully integrated CDMO; before that, he was the Head of Lonza's Viral Therapeutics Business Unit, which arose from the acquisition of Vivante GMP Solutions, a gene therapy CDMO that he founded and oversaw. David also has nearly fifteen years of CDMO client experience, having served as the first employee and Senior Vice President of Operations at Introgen Therapeutics, Inc., one of the world's first gene therapy development companies, where he oversaw the

establishment of the first commercial-scale viral vector facility in the United States.

Dr. Martin Pule's appointment to the Scientific Advisory Board brings extensive knowledge and experience in the genetic engineering of T cells for cancer treatment, with a particular emphasis on Chimeric Antigen Receptors ("CARs" or "CAR T cells"). Dr. Pule is a Clinical Senior Lecturer in the Department of Haematology at University College London's Cancer Institute and an Honorary Consultant in Haematology at University College Hospital, where he researches the genetic engineering of T cells for cancer treatment. The European Patent Office has named Dr. Pule the second most prolific inventor of CAR T cells and the most prolific inventor in 2019 and 2020, respectively.

Dr. Pule began his career in T-cell engineering as a Fulbright Scholar at the Center for Cell and Gene Therapy at Baylor College of Medicine in Houston in 2001. Dr. Pule founded and directed the UCL Chimeric Antigen Receptor (CAR) program and is the Founder and Chief Scientist Officer of Autolus Therapeutics, a market leader in T-cell programming technologies. He was the first to describe third-generation CARs and led one of the world's first CAR clinical studies that demonstrated efficacy in a solid cancer. He has filed over 50 patent families and has published extensively in peer-reviewed medical journals, with over 10,000 citations to date.